Please provide your email address to receive an email when new articles are posted on . Intra-arterial alteplase after successful reperfusion with mechanical thrombectomy for large vessel occlusion ...
In a multicenter Chinese trial involving 656 patients with large-vessel occlusion, endovascular thrombectomy was noninferior, within a 20% margin of confidence, to endovascular thrombectomy with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Stroke patients ...
Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...
The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...
Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...
PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Just a month after trial results appeared to dampen prospects for the use of intra-arterial thrombolysis on top of stroke thrombectomy in patients with large-vessel occlusions (LVOs), two new trials ...
Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors PURPOSE: To determine whether cryopreserved solutions of ...
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...
ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback